196 related articles for article (PubMed ID: 29264626)
41. Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study.
Martinez-Laguna D; Nogues X; Abrahamsen B; Reyes C; Carbonell-Abella C; Diez-Perez A; Prieto-Alhambra D
Osteoporos Int; 2017 Sep; 28(9):2573-2581. PubMed ID: 28744600
[TBL] [Abstract][Full Text] [Related]
42. Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer's Disease: A Nested Case-Control Study.
Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
J Alzheimers Dis; 2017; 56(1):119-128. PubMed ID: 27911327
[TBL] [Abstract][Full Text] [Related]
43. Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis.
Imfeld P; Bodmer M; Jick SS; Meier CR
Drug Saf; 2018 Dec; 41(12):1387-1396. PubMed ID: 30146658
[TBL] [Abstract][Full Text] [Related]
44. Risk of fragility fracture among patients with late-onset psoriasis: a UK population-based study.
Paskins Z; Whittle R; Abdul Sultan A; Muller S; Blagojevic-Bucknall M; Helliwell T; Packham J; Hider S; Roddy E; Mallen C
Osteoporos Int; 2018 Jul; 29(7):1659-1664. PubMed ID: 29574516
[TBL] [Abstract][Full Text] [Related]
45. Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.
Tzeng HE; Muo CH; Chen HT; Hwang WL; Hsu HC; Tsai CH
BMC Musculoskelet Disord; 2015 May; 16():123. PubMed ID: 25989902
[TBL] [Abstract][Full Text] [Related]
46. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
47. Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population-based nested case-control study.
Kumar S; Drake MT; Schleck CD; Johnson ML; Alexander JA; Katzka DA; Iyer PG
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1094-1102. PubMed ID: 28980336
[TBL] [Abstract][Full Text] [Related]
48. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
Butt DA; Mamdani M; Gomes T; Lix L; Lu H; Tu K;
J Bone Miner Res; 2014 Nov; 29(11):2483-8. PubMed ID: 24806397
[TBL] [Abstract][Full Text] [Related]
49. Development of a risk assessment tool for osteoporotic fracture prevention: A claims data approach.
Reber KC; König HH; Becker C; Rapp K; Büchele G; Mächler S; Lindlbauer I
Bone; 2018 May; 110():170-176. PubMed ID: 29421456
[TBL] [Abstract][Full Text] [Related]
50. Risk of fracture in patients with muscular dystrophies.
Pouwels S; de Boer A; Leufkens HG; Weber WE; Cooper C; van Onzenoort HA; de Vries F
Osteoporos Int; 2014 Feb; 25(2):509-18. PubMed ID: 23948807
[TBL] [Abstract][Full Text] [Related]
51. Acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate Alzheimer's disease.
Rozzini L; Vicini Chilovi B; Bertoletti E; Trabucchi M; Padovani A
Aging Clin Exp Res; 2007 Jun; 19(3):220-3. PubMed ID: 17607090
[TBL] [Abstract][Full Text] [Related]
52. Number of daily antihypertensive drugs and the risk of osteoporotic fractures in older hypertensive adults: National health insurance service - Senior cohort.
Kim SY; Kim S; Choi SE; Kim BS; Choi HR; Hwang D; Won CW
J Cardiol; 2017 Jul; 70(1):80-85. PubMed ID: 27884579
[TBL] [Abstract][Full Text] [Related]
53. Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care.
Lapi F; Simonetti M; Michieli R; Pasqua A; Brandi ML; Frediani B; Cricelli C; Mazzaglia G
Bone; 2012 Jan; 50(1):85-90. PubMed ID: 21985999
[TBL] [Abstract][Full Text] [Related]
54. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.
Miller DP; Watkins SE; Sampson T; Davis KJ
Phys Sportsmed; 2010 Dec; 38(4):19-27. PubMed ID: 21150138
[TBL] [Abstract][Full Text] [Related]
55. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
McCloskey EV; Johansson H; Oden A; Austin M; Siris E; Wang A; Lewiecki EM; Lorenc R; Libanati C; Kanis JA
J Bone Miner Res; 2012 Jul; 27(7):1480-6. PubMed ID: 22431426
[TBL] [Abstract][Full Text] [Related]
56. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease - exposure-matched cohort study.
Tolppanen AM; Taipale H; Tanskanen A; Tiihonen J; Hartikainen S
BMC Geriatr; 2016 Dec; 16(1):204. PubMed ID: 27908278
[TBL] [Abstract][Full Text] [Related]
57. Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.
Tai SY; Chen CH; Chien CY; Yang YH
BMC Neurol; 2017 Feb; 17(1):40. PubMed ID: 28231822
[TBL] [Abstract][Full Text] [Related]
58. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
Vinogradova Y; Dening T; Hippisley-Cox J; Taylor L; Moore M; Coupland C
BMJ; 2021 Sep; 374():n2182. PubMed ID: 34588168
[TBL] [Abstract][Full Text] [Related]
59. Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.
Åivo J; Kurki S; Sumelahti ML; Hänninen K; Ruutiainen J; Soilu-Hänninen M
Acta Neurol Scand; 2017 May; 135(5):516-521. PubMed ID: 27334254
[TBL] [Abstract][Full Text] [Related]
60. The risk of fracture in patients with multiple sclerosis: the UK general practice research database.
Bazelier MT; van Staa T; Uitdehaag BM; Cooper C; Leufkens HG; Vestergaard P; Bentzen J; de Vries F
J Bone Miner Res; 2011 Sep; 26(9):2271-9. PubMed ID: 21557309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
